Affinivax CEO and leadership

Steve Brugger brings over 30 years of experience in the biotech and pharmaceutical industry to Affinivax. He most recently served as the Chief Executive Officer of Visterra, a private biotech company based in Cambridge, Mass. During his tenure at Visterra, Steve led the company in closing a Series A round of financing, advancing its lead antibody program toward IND, and establishing strategic partnerships with both Pfizer and the Bill & Melinda Gates Foundation. Prior to Visterra, Steve was the Chief Operating Officer at Momenta Pharmaceuticals. While at Momenta, Steve held several leadership roles as the company grew from a private start-up to a successful public-traded biotechnology company. Prior to Momenta, Steve held various leadership and management positions at Millennium, Novartis, Ayerst, and Hoechst Pharmaceuticals. Steve received his BA in Biology from Susquehanna University and his MBA from the Rutgers Graduate School of Management.

Dr. Kamran Tavangar is a Chief Operating Officer at Affinivax Inc and is based in United States.

Strategic biotech finance leader with broad experience across the biopharma value chain. P&L management experience for $7B commercial business and $1.6B R&D budget. Experience with product launch planning and execution across Oncology (TIBSOVO), Rare Disease (SPINRAZA), Multiple Sclerosis (TECFIDERA, PLEGRIDY) and Hemophilia (ALPROLIX, ELOCTATE). Experience at both large and small companies building high-performing teams and developing talent. Demonstrated effectiveness in combining strategic frameworks, deep analytical capabilities and cross-functional leadership to drive decision making, align resource allocation to strategy, and design, implement and manage new processes. Previous professional experience in management consulting, software development and teaching. Academic training as a research chemist.

Dr. Kamran Tavangar is a Chief Operating Officer at Affinivax Inc and is based in United States.

Steve Brugger brings over 30 years of experience in the biotech and pharmaceutical industry to Affinivax. He most recently served as the Chief Executive Officer of Visterra, a private biotech company based in Cambridge, Mass. During his tenure at Visterra, Steve led the company in closing a Series A round of financing, advancing its lead antibody program toward IND, and establishing strategic partnerships with both Pfizer and the Bill & Melinda Gates Foundation. Prior to Visterra, Steve was the Chief Operating Officer at Momenta Pharmaceuticals. While at Momenta, Steve held several leadership roles as the company grew from a private start-up to a successful public-traded biotechnology company. Prior to Momenta, Steve held various leadership and management positions at Millennium, Novartis, Ayerst, and Hoechst Pharmaceuticals. Steve received his BA in Biology from Susquehanna University and his MBA from the Rutgers Graduate School of Management.